ArticleJournal of cosmetic dermatology2026
Objective Assessment of the Onset of RelabotulinumtoxinA in the Elevation of the Eyebrow and Its Clinical Implications.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe new ready-to-use botulinum toxins effectively treat lateral canthal lines; there is still little data on their efficacy in treating glabellar lines. The combined treatment of lateral canthal and glabellar lines allows the eyebrow to be repositioned.
aimsTo show the onset and action of RelabotulinumtoxinA on the periocular area, by measuring the variations of the area under the eyebrow in a real-life setting. PATIENTS/
methodsIn this real-life, multi-center case series, 36 patients (30 women, 6 men), aged 30-62 years, were treated with RelabotulinumtoxinA in glabellar and lateral canthal areas; patients were treated on day 0 (T0) and followed until day 30. Photos taken at T0 and at all follow-up time points were compared in calculating the median of the palpebral surface.
resultsAll patients responded to the treatment. Most of RelabotulinumtoxinA's effect on eyebrow position (76.25%) was seen within day 2, peaking in the first 24 h. The variation rate sharply declines by day 7. Patients showed a median increase in the exposed eyelid area of +11.91% compared to T0.
conclusionsIn the real-world setting, RelabotulinumtoxinA showed efficacy in treating GLs and LCLs. In the post-intervention phases (follow-up and potential touch-ups), the fast onset of the ready-to-use product can save time. The palpebral area measurement technique, which was selected to assess objectively the response, may allow for a higher level of precision than measuring distances in the periocular range and can be helpful in this type of study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.